Type 1 Diabetes
Conditions
Brief summary
The purpose of this research study is to understand how type 1 diabetes (T1D) increases the risk for cardiovascular diseases (heart attack and stroke). To this end, the investigators will compare apolipoprotein and triglyceride kinetics in people wtih T1D and healthy control participants.
Detailed description
Not required
Interventions
OTHERMetabolic testing
Participants will complete a metabolic testing protocol that includes intravenous infusion of stable isotope labeled tracers and blood sampling to determine lipoprotein kinetics
Sponsors
University of Missouri-Columbia
University of Washington
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
Cross-sectional comparison (T1D vs healthy control)
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Age: ≥18 but ≤45 years * premenopausal/eumenorrheic and not pregnant or breastfeeding * non-obese (body mass index ≥18.5\<30.0 kg/m2) * Fasting plasma triglyceride \<150 mg/dL Additional inclusion criteria for control subjects: * Fasting plasma glucose \<100 mg/dL * Plasma glucose 2 h after a 75 g oral glucose challenge \<140 mg/dL * HbA1c \<5.6%. Additional inclusion criteria for subjects with T1DM: * stable insulin regimen (multiple daily insulin injections or continuous subcutaneous insulin) for at least 8 weeks before screening * no use of diabetes medications other than insulin * HbA1c \<8.0%, basal (overnight fasted) * no severe symptomatic hypoglycemic event associated with a seizure or requiring help from other people or a medical facility in the 6 months prior to screening or metabolic testing
Exclusion criteria
* more than 1.5 h of structured exercise/week * use of tobacco products, excessive amounts of alcohol, or dietary supplements and/or medications known to affect lipid metabolism * hypothyroidism or other disorders known to affect lipid metabolism * conditions that would make it impossible to complete the study protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Apolipoprotein C turnover rate | one time, at baseline (this is a cross-sectional, observational study, no intervention) | Apolipoprotein C turnover rate will be assessed by using an intravenous stable isotope labeled amino acid infusion |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Triglyceride turnover rate | one time, at baseline (this is a cross-sectional, observational study, no intervention) | Triglyceride turnover rate will be assessed by using an intravenous stable isotope labeled glycerol infusion |
| Apolipoprotein B-100 turnover rate | one time, at baseline (this is a cross-sectional, observational study, no intervention) | Apolipoprotein B-100 turnover rate will be assessed by using an intravenous stable isotope labeled amino acid infusion |
| Apolipoprotein C concentration | one time, at baseline (this is a cross-sectional, observational study, no intervention) | Apolipoprotein C concentration |
| Triglyceride concentration | one time, at baseline (this is a cross-sectional, observational study, no intervention) | Triglyceride concentration |
| Apolipoprotein B-100 concentration | one time, at baseline (this is a cross-sectional, observational study, no intervention) | Apolipoprotein B-100 concentration |
Countries
United States
Contacts
CONTACTAmanda Heider
CONTACTMittendorfer Lab
PRINCIPAL_INVESTIGATORBettina Mittendorfer
University of Missouri-Columbia
Outcome results
None listed